more

Aquestive Therapeutics (AQST)

(Delayed Data from NSDQ)

$5.52 USD

+0.03 (0.55%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $5.52 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

Industry Rank:

Top 32% (79 out of 250)

Industry: Medical - Drugs

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Aquestive Therapeutics (AQST) Declines More Than Market: Some Information for Investors

by Zacks Equity Research Published on January 17,2024

Aquestive Therapeutics (AQST) closed at $2.63 in the latest trading session, marking a -1.13% move from the prior day.

AQSTPositive Net Change

Here's Why Aquestive Therapeutics (AQST) Fell More Than Broader Market

by Zacks Equity Research Published on January 11,2024

The latest trading day saw Aquestive Therapeutics (AQST) settling at $2.51, representing a -1.95% change from its previous close.

AQSTPositive Net Change

Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel

by Zacks Equity Research Published on January 08,2024

Following the FDA approval, Ligand's (LGND) Zelsuvmi is the first at-home treatment option available for molluscum contagiosum.

Merck (MRK) Begins Pivotal Studies on Four Cancer Candidates

by Zacks Equity Research Published on January 08,2024

Merck (MRK) begins global pivotal studies on bomedemstat, nemtabrutinib, MK-2870 and MK-5684.

pharmaceuticals

Allogene (ALLO) Down 20% on Strategic Changes in Pipeline

by Zacks Equity Research Published on January 05,2024

Allogene (ALLO) decides to deprioritize two pivotal studies for the third-line treatment of certain lymphoma patients and start a new study to focus on the first-line treatment of the indication.

Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study

by Zacks Equity Research Published on January 04,2024

Data from a late-stage study shows that non-transfusion-dependent thalassemia patients who received Agios' (AGIO) mitapivat demonstrated a statistically significant increase in hemoglobin response.

Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo

by Zacks Equity Research Published on January 04,2024

Daiichi Sankyo amends its existing collaboration with Esperion (ESPR), including the resolution of a commercial dispute over milestone payments. This amendment is valued at $125 million.

medical

Here's Why You Should Invest in Adverum (ADVM) Stock Now

by Zacks Equity Research Published on January 04,2024

Here, we discuss some reasons why buying Adverum Biotechnologies (AQST) stock now may turn out to be a prudent move.

biotechs

Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now

by Zacks Equity Research Published on January 03,2024

Here, we discuss some reasons why buying Rigel Pharmaceuticals (RIGL) stock now may turn out to be a prudent move.

pharmaceuticals

Here's Why You Should Invest in Aquestive (AQST) Stock Now

by Zacks Equity Research Published on January 03,2024

Here, we discuss some reasons why buying Aquestive Therapeutics (AQST) stock now may turn out to be a prudent move.

pharmaceuticals

Eli Lilly (LLY) Stock Up 57% in 2023: Will the Uptrend Continue?

by Zacks Equity Research Published on January 02,2024

Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.

pharmaceuticals

Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?

by Zacks Equity Research Published on December 29,2023

Here is how Aquestive Therapeutics (AQST) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics

by Zacks Equity Research Published on December 27,2023

Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog.

medical

What Awaits These 4 Drug Stocks That More Than Doubled in 2023?

by Ahan Chakraborty Published on December 26,2023

Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on December 13,2023

Here is how Aquestive Therapeutics (AQST) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.

Best Momentum Stock to Buy for December 7th

by Zacks Equity Research Published on December 07,2023

AQST and VVI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 7, 2023.

Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene

by Zacks Equity Research Published on December 07,2023

Syros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia.